Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Iteos Therapeutics Inc's Business Segments
Iteos Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
-
Regions Reported
-
Iteos Therapeutics Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Gal-301 Clinical Study0%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Gal-301 Clinical Study | - | 0% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Iteos Therapeutics Inc
Iteos Therapeutics Inc.
is a clinical-stage biotechnology company that was founded in 2011 in Belgium.
The company is focused on developing immuno-oncology therapies that can activate the patient's immune system to fight cancer.
They aim to provide cancer patients with long-lasting and meaningful clinical benefit.
Iteos has developed a proprietary platform technology that identifies novel targets for cancer immunotherapy.
Their lead product candidate is an anti-TIGIT antibody, which is currently in Phase 1/2 clinical trials for a range of solid tumor types.
The company also has several other drug candidates in its pipeline, including an anti-CD39 antibody and a STING agonist.
The company has extensive collaborations with academic institutions and pharmaceutical companies, including GlaxoSmithKline, Merck, and Sanofi.
These collaborations enable them to access expertise and resources that enhance their research capabilities.
Iteos has a global presence and operates from its headquarters in Cambridge, Massachusetts, and also has European offices in Gosselies, Belgium.
The company has raised significant funding from venture capital firms and public offerings, including a successful initial public offering in July 2020, raising $201.6 million.
Overall, Iteos Therapeutics is a promising biotechnology company that has made significant progress in developing innovative immuno-oncology therapies.
With a strong pipeline, collaborations, and ample funding, the company has the potential to make a significant impact in fighting cancer.
is a clinical-stage biotechnology company that was founded in 2011 in Belgium.
The company is focused on developing immuno-oncology therapies that can activate the patient's immune system to fight cancer.
They aim to provide cancer patients with long-lasting and meaningful clinical benefit.
Iteos has developed a proprietary platform technology that identifies novel targets for cancer immunotherapy.
Their lead product candidate is an anti-TIGIT antibody, which is currently in Phase 1/2 clinical trials for a range of solid tumor types.
The company also has several other drug candidates in its pipeline, including an anti-CD39 antibody and a STING agonist.
The company has extensive collaborations with academic institutions and pharmaceutical companies, including GlaxoSmithKline, Merck, and Sanofi.
These collaborations enable them to access expertise and resources that enhance their research capabilities.
Iteos has a global presence and operates from its headquarters in Cambridge, Massachusetts, and also has European offices in Gosselies, Belgium.
The company has raised significant funding from venture capital firms and public offerings, including a successful initial public offering in July 2020, raising $201.6 million.
Overall, Iteos Therapeutics is a promising biotechnology company that has made significant progress in developing innovative immuno-oncology therapies.
With a strong pipeline, collaborations, and ample funding, the company has the potential to make a significant impact in fighting cancer.
Iteos Therapeutics Inc. Overview
Iteos Therapeutics Inc. is a prominent biotechnology company dedicated to the advancement of next-generation cancer immunotherapies. The company focuses primarily on discovering and developing innovative small molecule drugs designed to target immune checkpoints and enzymes within the tumor microenvironment, thereby enhancing anti-tumor immunity and providing more effective treatment options for cancer patients.
Segments
Iteos Therapeutics operates exclusively within the biotechnology segment. This singular focus allows the company to concentrate its resources and expertise on the research, development, and commercialization of novel therapeutic agents aimed at treating various forms of cancer. The biotechnology segment encompasses activities related to:
- Discovery: Identifying and validating novel therapeutic targets related to cancer immunology.
- Preclinical Development: Conducting laboratory studies and early-stage experiments to assess the efficacy and safety of new compounds.
- Clinical Development: Advancing selected drug candidates through various phases of clinical trials to evaluate their performance in human subjects.
Products
Iteos Therapeutics is actively developing a robust pipeline of small molecule drugs, each targeting specific immune checkpoint pathways or tumor microenvironment enzymes. Key products in development include:
1. EOS-850:
- Target: TIGIT (T-cell immunoreceptor with Ig and ITIM domains).
- Mechanism: This drug inhibits TIGIT, a checkpoint receptor that negatively regulates T-cell activity. By blocking TIGIT, EOS-850 aims to enhance T-cell-mediated anti-tumor responses and improve immune system efficacy against cancer cells.
2. EOS-448:
- Target: LAG-3 (Lymphocyte-activation gene 3).
- Mechanism: EOS-448 is designed to inhibit LAG-3, which plays a crucial role in dampening immune responses. By targeting this checkpoint, the drug seeks to reinvigorate T-cell function and augment the immune response against tumors.
3. EOS-936:
- Target: ADORA2A (Adenosine A2A receptor).
- Mechanism: This drug targets the ADORA2A receptor, which is linked to immune suppression within the tumor microenvironment. By antagonizing this receptor, EOS-936 aims to restore anti-tumor immunity and inhibit tumor growth.
Services
In addition to its drug development initiatives, Iteos Therapeutics offers a variety of collaborative services aimed at enhancing cancer immunotherapy research and development. These services include:
- Collaborative Development: Iteos partners with academic institutions, pharmaceutical companies, and biotech organizations to conduct joint research on new therapeutic candidates. This includes sharing expertise and resources to optimize drug candidates for clinical use.
- Preclinical Research Services: The company provides comprehensive preclinical research services to external organizations. These services include:
- Assay Development: Designing and validating biological assays to evaluate the activity and effectiveness of drug candidates.
- In Vitro Testing: Conducting laboratory experiments to assess the pharmacological properties of compounds against cancer cell lines.
- Animal Model Creation: Developing relevant animal models for the study of cancer therapeutics and their effects in vivo.
- Data Analysis: Offering analytical support to interpret research findings, ensuring that data is effectively utilized in the development process.
- Consultation in Cancer Biology and Immunology: Iteos Therapeutics extends its expertise in cancer biology and immunology to assist other entities in the development of cancer immunotherapeutics. This includes providing strategic guidance on mechanisms of action, potential therapeutic strategies, and translational research.
Conclusion
Iteos Therapeutics Inc. stands at the forefront of cancer immunotherapy innovation, with a clear focus on developing targeted small molecule drugs that enhance immune responses against tumors. Through its commitment to research, development, and collaboration within the biotechnology landscape, the company aims to significantly improve treatment outcomes for cancer patients worldwide.
Iteos Therapeutics Inc. is a prominent biotechnology company dedicated to the advancement of next-generation cancer immunotherapies. The company focuses primarily on discovering and developing innovative small molecule drugs designed to target immune checkpoints and enzymes within the tumor microenvironment, thereby enhancing anti-tumor immunity and providing more effective treatment options for cancer patients.
Segments
Iteos Therapeutics operates exclusively within the biotechnology segment. This singular focus allows the company to concentrate its resources and expertise on the research, development, and commercialization of novel therapeutic agents aimed at treating various forms of cancer. The biotechnology segment encompasses activities related to:
- Discovery: Identifying and validating novel therapeutic targets related to cancer immunology.
- Preclinical Development: Conducting laboratory studies and early-stage experiments to assess the efficacy and safety of new compounds.
- Clinical Development: Advancing selected drug candidates through various phases of clinical trials to evaluate their performance in human subjects.
Products
Iteos Therapeutics is actively developing a robust pipeline of small molecule drugs, each targeting specific immune checkpoint pathways or tumor microenvironment enzymes. Key products in development include:
1. EOS-850:
- Target: TIGIT (T-cell immunoreceptor with Ig and ITIM domains).
- Mechanism: This drug inhibits TIGIT, a checkpoint receptor that negatively regulates T-cell activity. By blocking TIGIT, EOS-850 aims to enhance T-cell-mediated anti-tumor responses and improve immune system efficacy against cancer cells.
2. EOS-448:
- Target: LAG-3 (Lymphocyte-activation gene 3).
- Mechanism: EOS-448 is designed to inhibit LAG-3, which plays a crucial role in dampening immune responses. By targeting this checkpoint, the drug seeks to reinvigorate T-cell function and augment the immune response against tumors.
3. EOS-936:
- Target: ADORA2A (Adenosine A2A receptor).
- Mechanism: This drug targets the ADORA2A receptor, which is linked to immune suppression within the tumor microenvironment. By antagonizing this receptor, EOS-936 aims to restore anti-tumor immunity and inhibit tumor growth.
Services
In addition to its drug development initiatives, Iteos Therapeutics offers a variety of collaborative services aimed at enhancing cancer immunotherapy research and development. These services include:
- Collaborative Development: Iteos partners with academic institutions, pharmaceutical companies, and biotech organizations to conduct joint research on new therapeutic candidates. This includes sharing expertise and resources to optimize drug candidates for clinical use.
- Preclinical Research Services: The company provides comprehensive preclinical research services to external organizations. These services include:
- Assay Development: Designing and validating biological assays to evaluate the activity and effectiveness of drug candidates.
- In Vitro Testing: Conducting laboratory experiments to assess the pharmacological properties of compounds against cancer cell lines.
- Animal Model Creation: Developing relevant animal models for the study of cancer therapeutics and their effects in vivo.
- Data Analysis: Offering analytical support to interpret research findings, ensuring that data is effectively utilized in the development process.
- Consultation in Cancer Biology and Immunology: Iteos Therapeutics extends its expertise in cancer biology and immunology to assist other entities in the development of cancer immunotherapeutics. This includes providing strategic guidance on mechanisms of action, potential therapeutic strategies, and translational research.
Conclusion
Iteos Therapeutics Inc. stands at the forefront of cancer immunotherapy innovation, with a clear focus on developing targeted small molecule drugs that enhance immune responses against tumors. Through its commitment to research, development, and collaboration within the biotechnology landscape, the company aims to significantly improve treatment outcomes for cancer patients worldwide.